Michael N Cocchi1, Myles D Boone2, Brandon Giberson3, Tyler Giberson3, Emily Farrell3, Justin D Salciccioli3, Daniel Talmor2, Donna Williams4, Michael W Donnino5. 1. Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA Department of Anesthesia Critical Care, Division of Critical Care, Beth Israel Deaconess Medical Center, Boston, MA, USA mcocchi@bidmc.harvard.edu. 2. Department of Anesthesia Critical Care, Division of Critical Care, Beth Israel Deaconess Medical Center, Boston, MA, USA. 3. Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA. 4. Department of Medicine, Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA, USA. 5. Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA Department of Medicine, Division of Pulmonary Critical Care, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Abstract
BACKGROUND: Induction of mild therapeutic hypothermia (TH; temperature 32-34°C) has become standard of care in many hospitals for comatose survivors of cardiac arrest. Pyrexia, or fever, is known to be detrimental in patients with neurologic injuries such as stroke or trauma. The incidence of pyrexia in the postrewarming phase of TH is unknown. We attempted to determine the incidence of fever after TH and hypothesized that those patients who were febrile after rewarming would have worse clinical outcomes than those who maintained normothermia in the postrewarming period. METHODS: Retrospective data analysis of survivors of out-of-hospital cardiac arrest (OHCA) over a period of 29 months (December 2007 to April 2010). INCLUSION CRITERIA: OHCA, age >18, return of spontaneous circulation, and treatment with TH. EXCLUSION CRITERIA: traumatic arrest and pregnancy. Data collected included age, sex, neurologic outcome, mortality, and whether the patient developed fever (temperature > 100.4°F, 38°C) within 24 hours after being fully rewarmed to a normal core body temperature after TH. We used simple descriptive statistics and Fisher exact test to report our findings. RESULTS: A total of 149 patients were identified; of these, 82 (55%) underwent TH. The mean age of the TH cohort was 66 years, and 28 (31%) were female. In all, 54 patients survived for >24 hours after rewarming and were included in the analysis. Among the analyzed cohort, 28 (52%) of 54 developed fever within 24 hours after being rewarmed. Outcome measures included in-hospital mortality as well as neurologic outcome as defined by a dichotomized Cerebral Performance Category (CPC) score. When comparing neurologic outcomes between the groups, 16 (57%) of 28 in the postrewarming fever group had a poor outcome (CPC score 3-5), while 15 (58%) of 26 in the no-fever group had a favorable outcome (P = .62). In the fever group, 15 (52%) of 28 died, while in the no-fever group, 14 (54%) of 26 died (P = .62). CONCLUSION: Among a cohort of patients who underwent mild TH after OHCA, more than half of these patients developed pyrexia in the first 24 hours after rewarming. Although there were no significant differences in outcomes between febrile and nonfebrile patients identified in this study, these findings should be further evaluated in a larger cohort. Future investigations may be needed to determine whether postrewarming temperature management will improve the outcomes in this population.
BACKGROUND: Induction of mild therapeutic hypothermia (TH; temperature 32-34°C) has become standard of care in many hospitals for comatose survivors of cardiac arrest. Pyrexia, or fever, is known to be detrimental in patients with neurologic injuries such as stroke or trauma. The incidence of pyrexia in the postrewarming phase of TH is unknown. We attempted to determine the incidence of fever after TH and hypothesized that those patients who were febrile after rewarming would have worse clinical outcomes than those who maintained normothermia in the postrewarming period. METHODS: Retrospective data analysis of survivors of out-of-hospital cardiac arrest (OHCA) over a period of 29 months (December 2007 to April 2010). INCLUSION CRITERIA: OHCA, age >18, return of spontaneous circulation, and treatment with TH. EXCLUSION CRITERIA: traumatic arrest and pregnancy. Data collected included age, sex, neurologic outcome, mortality, and whether the patient developed fever (temperature > 100.4°F, 38°C) within 24 hours after being fully rewarmed to a normal core body temperature after TH. We used simple descriptive statistics and Fisher exact test to report our findings. RESULTS: A total of 149 patients were identified; of these, 82 (55%) underwent TH. The mean age of the TH cohort was 66 years, and 28 (31%) were female. In all, 54 patients survived for >24 hours after rewarming and were included in the analysis. Among the analyzed cohort, 28 (52%) of 54 developed fever within 24 hours after being rewarmed. Outcome measures included in-hospital mortality as well as neurologic outcome as defined by a dichotomized Cerebral Performance Category (CPC) score. When comparing neurologic outcomes between the groups, 16 (57%) of 28 in the postrewarming fever group had a poor outcome (CPC score 3-5), while 15 (58%) of 26 in the no-fever group had a favorable outcome (P = .62). In the fever group, 15 (52%) of 28 died, while in the no-fever group, 14 (54%) of 26 died (P = .62). CONCLUSION: Among a cohort of patients who underwent mild TH after OHCA, more than half of these patients developed pyrexia in the first 24 hours after rewarming. Although there were no significant differences in outcomes between febrile and nonfebrile patients identified in this study, these findings should be further evaluated in a larger cohort. Future investigations may be needed to determine whether postrewarming temperature management will improve the outcomes in this population.
Authors: J Herlitz; E Andersson; A Bång; J Engdahl; M Holmberg; J lindqvist; B W Karlson; L Waagstein Journal: Eur Heart J Date: 2000-08 Impact factor: 29.983
Authors: Martin Christ; Katharina Isabel von Auenmueller; Jan Peter Noelke; Benjamin Sasko; Scharbanu Amirie; Hans-Joachim Trappe Journal: Intern Emerg Med Date: 2015-11-23 Impact factor: 3.397
Authors: Clifton W Callaway; Michael W Donnino; Ericka L Fink; Romergryko G Geocadin; Eyal Golan; Karl B Kern; Marion Leary; William J Meurer; Mary Ann Peberdy; Trevonne M Thompson; Janice L Zimmerman Journal: Circulation Date: 2015-11-03 Impact factor: 29.690
Authors: Young-Min Kim; Chun Song Youn; Soo Hyun Kim; Byung Kook Lee; In Soo Cho; Gyu Chong Cho; Kyung Woon Jeung; Sang Hoon Oh; Seung Pill Choi; Jong Hwan Shin; Kyoung-Chul Cha; Joo Suk Oh; Hyeon Woo Yim; Kyu Nam Park Journal: Crit Care Date: 2015-07-22 Impact factor: 9.097
Authors: Nicolai V Bogert; Isabella Werner; Angela Kornberger; Patrick Meybohm; Anton Moritz; Till Keller; Ulrich A Stock; Andres Beiras-Fernandez Journal: Sci Rep Date: 2016-02-25 Impact factor: 4.379
Authors: Hyoung Youn Lee; Dong Hun Lee; Byung Kook Lee; Kyung Woon Jeung; Yong Hun Jung; Seung Phil Choi; Jung Soo Park; Jae Hoon Lee; Kap Su Han; Yong Il Min Journal: J Clin Med Date: 2020-09-10 Impact factor: 4.241